Do red herrings swim in circles? Controlling for the endogeneity of time to death by Felder, Stefan et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Do red herrings swim in circles? Controlling for the endogeneity
of time to death 
Felder, S; Werblow, A; Zweifel, P
Felder, S; Werblow, A; Zweifel, P (2010). Do red herrings swim in circles? Controlling for the endogeneity of time
to death. Journal of Health Economics, 29(2):205-212.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Health Economics 2010, 29(2):205-212.
Felder, S; Werblow, A; Zweifel, P (2010). Do red herrings swim in circles? Controlling for the endogeneity of time
to death. Journal of Health Economics, 29(2):205-212.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Health Economics 2010, 29(2):205-212.
Stefan Felder, Andreas Werblow and Peter Zweifel*
Do Red Herrings Swim in Circles? –
Controlling for the Endogeneity of Time to Death
Abstract
Studies on the effect of ageing on health care expenditures (HCE) have re-
vealed the importance of controlling for time-to-death (TTD). These studies,
however, are subject to possible endogeneity if HCE influences remaining life
expectancy. This paper introduces a ten year observational period on monthly
HCE, socioeconomic characteristics, and survivor status to first predict TTD
and then uses predicted values of TTD as an instrument in the regression for
HCE. While exogeneity of TTD has to be rejected, core results concerning the
role of TTD rather than age as a determinant of HCE (the “red herring” hy-
pothesis) are confirmed.
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1. Introduction 
This paper seeks to add to the debate on the ‘red herring’ hypothesis, viz. the claim that 
population ageing will not have a significant impact on health care expenditure (HCE) 
(Zweifel et al., 1999). Several authors (Salas and Raftery, 2001, Seshamani and Gray, 2004) 
disputed the robustness of these findings, pointing to potential weaknesses in the econometric 
methodology. Their main arguments referred to multicollinearity between and endogeneity of 
the explanatory variables. Use of the Heckman model to deal with the fact that HCE are 
censored, zero-inflated, and roughly log-normally distributed may run into multicollinearity 
problems because the inverse Mill’s ratio λ is often highly correlated with the other 
explanatory variables. Regarding endogeneity, Salas and Raftery (2001) argued that time-to-
death (TTD) is influenced by current and previous HCE, causing OLS estimates to be biased 
and inconsistent. 
These methodological concerns were addressed in Zweifel et al., 2004) and Werblow et al., 
2007). Multicollinearity was at least mitigated by employing a two-part model in addition to 
the Heckman model. The two-part model separates the selection part (probability of positive 
HCE) from the equation for the level of HCE, serving to eliminate the correlation between the 
selection term λ and the other regressors as a source of multicollinearity. As to endogeneity, 
the solution adopted was to reduce the number of TTD indicators that may be influenced by 
HCE. Rather than using a panel data set with quarterly HCE up to the time of death for each 
deceased [as in Zweifel et al., 1999), where a set of potentially endogenous quarter dummies 
may cause problems], HCE of one year only was related to TTD. 
In this paper, the panel data set covers the years 1997 to 2006, permitting to use the first three 
years of monthly HCE and observed TTD values up to the end of 2002 to derive estimated 
TTD values for the 2003 to 2006 period (see Figure 1). With data of about 60,000 individuals 
of whom 11 percent died between 2000 and 2006, endogeneity of TTD can directly be tackled 
in this way.  
Accordingly, this paper is structured as follows. In section 2, monthly HCE covering 1997 to 
1999 are related to TTD of individuals who died between 2000 and 2002 or survived 
December 31, 2002 (Model 1, with maximum TTD set at 36 months; see Figure 1 again). 
Estimated coefficients then serve to calculate estimated TTD (TTD ) from individuals’ 
monthly HCE between 2000 and 2002. This variable serves as the main instrument in the 
instrumental variable (IV) estimation of model 2. In Section 3, annual HCE in 2003 is 
analyzed as a function of, age, TTD and other variables. In this model 2, maximum TTD is 36 
5 
months, attributed to a person who survived December 31, 2006. To avoid endogeneity, TTD 
values derived from model 1 enter the regression as instrument. Since the pertinent tests point 
to endogeneity of TTD, the question arises of whether the ‘red herring’ hypothesis is robust 
with regard to the measurement of time-to-death. This issue is taken up in Section 4, which 
presents a regression for HCE in 2003 that contains expected TTD estimated from past HCE 
and demographic factors but no survival information. According to our findings, time-to-
death continues to be a highly significant determinant of HCE, causing its age gradient to 
even become negative past the age of 60 at the latest. Section 5 summarizes and concludes. 
Figure 1: Setup of the study 
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2. Estimating TTD using monthly HCE covering three years 
Model 1 considers 8,650 individuals with residence in the Swiss cantons of Zurich and 
Geneva, of which 3,124 died between 2000 and 2002 and 5,526 survived to the end of 2002 
(see Table 1). Survivors represent a 10 percent sample randomly drawn from the population. 
Average TTD of the deceased is about 18 months; for the survivors, TTD is set to 36 months. 
The average age in 1999 of the deceased is 76 years, that of the survivors, 55 years. There is a 
3 percentage point larger share of men among the deceased than among the survivors, 
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reflecting their lower life expectancy. Zurich’s share is higher among the survivors than 
among the deceased, indicating a younger population in Zurich than in Geneva.  
Swiss social health insurance law allows individuals to choose higher deductibles. Among the 
deceased, one-fifth opted for high-deductible contracts, compared to one third among the 
survivors. Moral hazard effects not only emanate from medical insurance but also from other 
insurance coverage linked to health status (Zweifel and Manning, 2000). Notably, generous 
income replacement in the event of sickness or accident serves to further mitigate the 
financial consequences of an illness episode. For this reason, accident insurance is taken into 
account as well (to the extent that it is bought from the same health insurer). This option is 
often chosen by the elderly, while individuals in the labor force usually obtain accident 
insurance through their employer. This explains why the share of individuals combining 
health and accident insurance is much higher among the deceased. Roughly one-third of the 
insured opted for hospital supplementary insurance providing for amenities. Between 84 and 
94 percent chose at least one additional supplement to their health insurance policy (not 
detailed in Table 1). These supplements are also expected to give rise to (more limited) moral 
hazard effects.  
Table 1: Descriptive statistics I, 2000 
Deceased (n = 3,124) Survivors (n = 5,526)
Variable Mean SE Min Max Mean SE Min Max
Age 76.38 13.37 30 95  55.35 15.1 30 95 
Time to death in month 18.07 10.35 1 36  36.00 0 36 36 
Share of men 0.43 0.50 0 1  0.40 0.49 0 1 
Share of individuals from Zurich 0.67 0.46 0 1  0.78 0.41 0 1 
Share of individuals 
         
with higher deductibles 0.21 0.41 0 1  0.41 0.49 0 1 
with accident insurance 0.93 0.25 0 1  0.68 0.47 0 1 
with suppl. hospital insurance 0.32 0.47 0 1  0.44 0.50 0 1 
with other supplements 0.84 0.37 0 1  0.94 0.24 0 1 
Table 2 compares monthly HCE between deceased and surviving persons in the years 1997 to 
1999.1 The average HCE over the 36 months was 950 Swiss Francs (CHF, some US$ 630 at 
2006 exchange rates) for the deceased and 247 CHF for the survivors. Some 8 percent of the 
survivors and 3 percent of the deceased had zero HCE in all 36 months. About one-third of 
the survivors and two-thirds of the deceased had positive HCE in a given month, again 
pointing to higher (expected) HCE of the deceased. 
                                                
1
 HCE are expressed in CHF of 2006 
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Table 2: Descriptive statistics II, 1997-1999 
Month Variable 
Deceased  Survivors 
Mean SE Max Share of HCE>0 Mean SE Max 
Share of 
HCE>0 
12/1999 HCE m1 1185 1904 20632 0.67 219 219 682 0.34 
11/1999 HCE m2 1287 2156 24420 0.68 286 286 871 0.38 
10/1999 HCE m3 1326 2176 26044 0.68 299 299 977 0.35 
09/1999 HCE m4 1247 2295 43712 0.65 275 275 818 0.36 
08/1999 HCE m5 1264 2198 24486 0.64 255 255 892 0.32 
07/1999 HCE m6 1221 2449 52618 0.65 252 252 852 0.34 
06/1999 HCE m7 1127 2020 39665 0.66 277 277 843 0.37 
05/1999 HCE m8 1141 2253 41951 0.64 251 251 776 0.34 
04/1999 HCE m9 1120 2115 56078 0.63 267 267 905 0.34 
03/1999 HCE m10 1156 2104 22002 0.66 305 305 960 0.37 
02/1999 HCE m11 1006 2248 62890 0.60 246 246 902 0.33 
01/1999 HCE m12 1389 2347 23199 0.70 358 358 1043 0.40 
12/1998 804 1600 19277 0.57 190 190 704 0.31 
11/1998 949 1898 32298 0.60 232 232 748 0.34 
10/1999 1015 1970 29759 0.61 265 265 861 0.34 
09/1998 929 2118 48687 0.59 253 253 783 0.34 
08/1998 865 1963 45309 0.56 222 222 935 0.28 
07/1998 915 1919 36943 0.57 233 233 1047 0.30 
06/1998 837 1619 21411 0.57 263 263 1018 0.32 
05/1998 860 1807 29406 0.58 243 243 919 0.32 
04/1998 944 2040 32920 0.57 246 246 852 0.31 
03/1998 930 2039 28690 0.57 263 263 886 0.33 
02/1998 762 1669 27646 0.52 214 214 766 0.30 
01/1998 1247 2311 28059 0.65 332 332 944 0.37 
12/1997 633 1678 54217 0.50 174 174 652 0.29 
11/1997 676 1539 20575 0.52 205 205 634 0.31 
10/1997 795 1627 19985 0.57 248 248 937 0.32 
09/1997 738 1737 37988 0.53 243 243 833 0.31 
08/1997 712 1694 35524 0.49 209 209 819 0.27 
07/1997 755 1694 23159 0.51 210 210 801 0.28 
06/1997 639 1534 23032 0.51 215 215 907 0.30 
05/1997 712 2675 119964 0.50 202 202 678 0.29 
04/1997 731 1581 20890 0.54 244 244 833 0.32 
03/1997 643 1466 16087 0.51 196 196 645 0.28 
02/1997 580 1387 20290 0.48 205 205 710 0.29 
01/1997 1048 2144 25797 0.58 306 306 920 0.36 
01/1997-
12/1999 1-36HCE 950 1022 10952 0.97  247 247 389 0.92 
The time series of monthly HCE in Table 2 reveals a statistical artefact. In January, HCE are 
markedly higher than in December. This reflects a delay in claims processing by health care 
providers before Christmas that usually is made up in January. Apart from these peaks, there 
is a steady increase in the monthly real HCE of the deceased, while they remain relatively 
stable among the survivors. The steady rise of HCE as time proceeds reflects the shrinking 
remaining TTD among the deceased, i.e. of persons who were to die between 2000 and 2002.  
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Model 1 specifies the following equation with time to death observed in January 2000 as the 
dependent variable, 
( ) ( )
( ) ( )
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Explanatory variables include the logarithm of monthly HCE in 1999 and its squared values 
to reflect recent impacts and to allow for non-constant marginal returns; the average monthly 
HCE during in the three preceding years (1997 to 1999) and its squared value to reflect lagged 
influences and to neutralize the January spike found in Table 2, again admitting non-constant 
marginal returns; the number of months with positive HCE in 1999 and 1998, respectively, to 
have an indicator of subjective health status (on the premise that this is what determines the 
decision to initiate a health care episode); age and age squared, survivor status ( 1D =  if 
deceased); five dummy variables Ej indicating an individual’s canton of residence (Zurich = 1, 
Geneva = 0) and the four insurance parameters listed in Table 1, and an error term. Zero HCE 
observations were set equal to 1 in order to allow transformation to logarithms. 
Table 3 presents the estimation results for eq. (1). Turning first to the estimate including 
survivor status D, one finds that the coefficient for the linear effect of HCE on TTD ( 1α ) is 
positive while the coefficient for the squared effect ( 2α ) is negative. The combined marginal 
effect of an increase in HCE on TTD is positive for all months of 1999. For the deceased, it is 
negative in the last month (HCEm1), possibly pointing to the onset of decreasing marginal 
returns when the time of death is close. For the average monthly HCE between 1997 and 
1999, no significant effect on TTD is observable. The number of months with positive HCE in 
1999 is significant. However, while a high number of months with positive HCE in 1999 does 
point to a shorter remaining life expectancy, the reverse is true for 1998. Interestingly, neither 
age nor sex nor the presence of (other) insurance except supplementary hospital coverage 
constitute significant predictors. But the fact that the person died during the 36 months to 
come leads to the prediction that TTD is 17 months less. 
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Table 3:  Time to death (TTD) measured at the end of 1999, OLS estimation corrected 
for heteroskedasticity 
 With survival status Without survival status 
(1) (2) (3) (4)
Dep. Var. Coeff. Std. err. Coeff. Std. err.
InHCEm1 0.963** 0.1710 1.433** 0.2352 
InHCEm2 0.783** 0.1677 1.370** 0.2275 
lnHCEm3 0.497** 0.1653 0.905**  0.2311 
InHCEm4 0.541** 0.1703 0.991** 0.2293 
InHCEm5 0.481** 0.1667 1.030** 0.2300 
InHCEm6 0.568** 0.1665 0.886** 0.2268 
InHCEm7 0.570** 0.1681 0.915** 0.2297 
InHCEm8 0.552** 0.1683 0.959** 0.2313 
InHCEm9 0.402* 0.1695 0.817** 0.2333 
InHCEm10 0.476** 0.1690 0.811** 0.2336 
InHCEm11 0.511** 0.1667 0.696** 0.2239 
InHCEm12 0.517** 0.1639 0.910** 0.2231 
(InHCEm1)2 -0.123** 0.0210 -0.184** 0.0285 
(InHCEm2)2 -0.085** 0.0199 -0.147** 0.0269 
(InHCEm3)2 -0.043* 0.0196 -0.085** 0.0275 
(InHCEm4)2 -0.053** 0.0206 -0.096** 0.0276 
(InHCEm5)2 -0.042* 0.0199 -0.111** 0.0274 
(InHCEm6)2 -0.046* 0.0198 -0.078** 0.0267 
(InHCEm7)2 -0.054** 0.0199 -0.079** 0.0274 
(InHCEm8)2 -0.047* 0.0203 -0.081** 0.0282 
(InHCEm9)2 -0.033 0.0200 -0.069* 0.0276 
(InHCEm10)2 -0.034 0.0199 -0.059* 0.0276 
(InHCEm11)2 -0.044* 0.0198 -0.044 0.0263 
(InHCEm12)2 -0.037 0.0190 -0.070** 0.0258 
ln HCE 0.001 0.1292 0.988** 0.1933 
( ln HCE )2 -0.002 0.0247 -0.213** 0.0348 
n_99 -1.535** 0.3813 -2.581** 0.5221 
n_98 0.084* 0.0388 0.173** 0.0530 
Age 0.036 0.0290 0.297** 0.0375 
age2 0.000 0.0003 -0.004** 0.0003 
Sexm -0.248 0.1427 -2.222** 0.1984 
Zurich -0.029 0.1695 -0.703** 0.2412 
higher deductibles 0.021 0.1313 0.636** 0.1955 
accident insurance 0.015 0.1179 -0.566** 0.1914 
suppl. hospital 
coverage 
0.042 0.1371 0.529** 0.1946 
other supplements 0.504 0.2879 1.419** 0.3983 
survivor status -16.768** 0.2300   
Constant 34.664** 0.8399 29.647** 1.1129 
R^2 0.670  R^2 0.352 
Root MSE 6.121  Root MSE 8.5722 
F (37, 8612) 271.56  F (36, 8613) 121.48 
N 8,650  N 8,650 
Things change considerably when survival status is excluded (columns 3 and 4 of Table 3). 
The combined positive marginal effect of monthly HCE during 1999 is now reinforced and 
the marginal effect of average HCE during the last 36 months becomes significantly positive 
as well. Age, gender, and (other) insurance coverage become significant, with the expected 
signs. Finally the coefficient of determination drops 67 to 35 percent. 
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Since survival status cannot be known in a forecast, it is this second version of Model 1 that 
will be used to calculate the expected TTD of individuals at the end of 2002 (our instrument 
for the IV estimation in model 2), based on monthly HCE between 2000 and 2002 and the 
other explanatory variables.  
3. Testing for the endogeneity of time-to-death 
The second step consists in estimating HCE of 2003,  
2003 0 1 2HCE X TTDβ β β η= + + +  , (2) 
where X is a 1 L×  vector of exogenous explanatory variables, 1β  is a 1L×  coefficient vector, 
and η  an error term. For simplicity, eq. (2) denotes both elements of the two-part model. As 
shown in the preceding section, TTD is endogenous to HCE, implying that ( ) 0Cov TTD,η ≠ , 
causing coefficient estimates to be biased and inconsistent.2
The instrumental variable (IV) approach calls for replacing observed TTD by an estimate 
provided by an auxiliary regression that contains at least one variable z, which is not part of 
eq. (2). Such an estimate must meet the following requirements [Wooldridge (2009, ch. 
15.1)]: (i) it should be highly correlated with the endogenous variable, and (ii) it must not be 
correlated with the error term in (2). If condition (i) is violated, the equation designed to 
derive ‘purged’ values for the endogenous regressor is likely misspecified, imparting a risk of 
inconsistency to the estimation of eq. (2). If condition (ii) is violated, estimation of (2) is 
inconsistent with certainty. Since the regressors X listed in Table 1 are assumed to be 
exogenous, they belong to the reduced form given by
0 1 2TTD X Z uγ γ γ= + + +  . (3) 
Here, the vector Z contains the instruments. By construction, the TTD values derived from eq. 
(1) qualify as instruments, such that 
( )1 iz TTD α=   , (4) 
Here, αˆ  denotes the subset of estimated coefficients pertaining to the 12 lagged monthly 
HCE terms and their squared values and the other variables from eq. (1). Further candidates 
                                                
2
 Eq. (2) could include survival status (D) as well. This variable is likely also plagued by endogeneity. However, 
this problem will be neglected because there is a lack of instruments satisfying the conditions stated in the text. 
Moreover, including survival status as an exogenous variable does not produce reasonable IV-estimates, possibly 
due to the endogeneity of survival.  
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for instruments would be average monthly HCE during the past three years and the insurance 
variables comprising the vector E in eq. (1). 
Requirement (i) for valid instruments in the case of endogeneity can simply be tested by using 
regression (3). If 2 0γ ≠  holds, requirement (i) is met. Requirement (ii) calls for 2 0ρ =  in the 
regression, 
0 1 2ˆ .X Zη ρ ρ ρ ϖ= + + +   (5) 
The ηˆ  are the residuals calculated from eq. (2), and they should be uncorrelated with the 
instruments contained in Z. However, since there are more than one possible instrument for 
the one endogenous variable TTD, testing for the so-called overidentifying restriction is 
possible, indicating whether the excluded instruments are correctly excluded from eq. (5). 
This test can be performed using the ( )2 Qχ  distribution, with Q denoting the number of 
instruments. The test statistic is equal to NR2, with R2 estimated from (5) and N, the number of 
observations (Wooldridge 2002, p. 122). 
Once the set of valid instrument is established, we can test the exogeneity of TTD via a 
regression-based Hausman test which employs the estimated error term of the reduced 
equation (u ) (see equation (3)) as an additional explanatory variable in the structural form of 
the model (equation (2)). The null hypothesis of exogeneity of TTD can be tested by a simple 
t-test on the coefficients of u . Wooldridge (2002, p. 474) shows that this procedure is also 
appropriate in the case of Probit estimation. 
Eq. (2) was estimated as a two-part model, relating annual HCE of 2003 to TTD measured up 
to the end of 2006, with its maximum value again set at 36 months. Results for the two-part in 
Table 4 refer to the probability of incurring positive HCE.3 ‘While details of the reduced form 
equation (3) and the test equation (5) are not shown, ‘accident insurance’ (see Table 1) 
appears to be a valid instrument in addition to estimated TTD. In particular, both instruments 
passed the test for the overidentifying restrictions (see the right-hand side of Table 4). 
However, according to the Hausman test, one has to reject the null hypothesis of exogeneity 
for TTD, as evidenced by the ( )2 1χ test statistic (again on the right-hand side of Table 4). 
This might be due to autocorrelation in HCE. In that case, TTD  would pass the test eq. (5) 
which is based on contemporaneous values. Yet, through eq. (4) its values still would contain 
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 Actually, the threshold is set at CHF 230 rather than zero. The minimum annual deductible was CHF 230 at the 
time, preventing the insured from submitting bills below that threshold. 
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error components of previous HCE, which would cause it to correlate with the error term η of 
eq. (2). Without pursuing this further, the conclusion is that, the two instruments retained, 
TTD  and ‘accident insurance’, are not fully valid. 
Table 4: Probit estimation for HCE > 230 CHF, 2003 
Probit IV Probit 
(1)
Coeff. 
(2) 
Robust std. err. 
(3)
Coeff. 
(4)
Robust std. err. 
TTD -0.018** 0.002 -0.030** 0.003 
Age -0.155** 0.019 -0.167** 0.019 
Age2/1000 2.913** 0.341 3.167** 0.336 
Age3/1000 0.015** 0.002 -0.017** 0.002 
Sexm -0.932** 0.058 -0.918** 0.058 
Sexm*Age 0.010** 0.001 0.010** 0.001 
Zurich -0.329** 0.021 -0.329** 0.021 
Higher deductible -0.500** 0.014 -0.497** 0.014 
Suppl. hospital cov. 0.121** 0.015 0.122** 0.015 
Other supplements 0.297** 0.026 0.303** 0.026 
Constant 3.948** 0.366 4.575** 0.373 
Number of observations  46,299 46,299  
Wald χ2 (10) 5.249  Wald χ2 (10) 5,593 
Pseudo R-squared 0.129  Hausman test of exogeneity
χ2 (1) = 66.49 (p = 0.001) 
Test of overidentifying restrictions:
χ2 (1) = 2.92 (p = 0.09)  
Note that controlling for endogeneity of TTD is important, its coefficient changing from -0.18 
in the Probit estimation to -0.30 in the IV estimation. This result also arises if the second 
instrument ‘accident insurance’ is dropped from the equation. Therefore, the effect of TTD on 
HCE is even reinforced rather than weakened, contrary to expectations. All the other 
coefficients prove rather robust. 
Table 5 reports on the IV regression of positive HCE. Here, no set of instruments satisfying 
both validity requirements was found. With TTD  only, the Hausman test rejects the null 
hypothesis of exogeneity. Since eq. (3) is now just identified, testing for overidentifying 
restrictions coming from additional instruments is not possible. However, the transition to IV 
estimation has a similar effect as in the Probit part of the model in that the coefficient at TTD
increases in absolute value. The results thus are somewhat inconclusive. While exogeneity of 
TTD is rejected and instruments are “strong”4, the instruments used for purging TTD of its 
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 The weakness of instruments can be tested by the so called concentration parameter – a test of instruments in 
the reduced equation (Stock et al. 2002). 
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endogeneity are possibly not valid. If endogeneity is not controlled for, the effect of TTD on 
HCE is underestimated. However, the appropriate tests reveal that it is extremely difficult to 
find valid instruments. This hints to unobserved variables influencing the error terms in eq. 
(2), such as morbidity indicators.
Table 5: OLS and IV estimation for ln HCE | HCE > 230 CHF, 2003 
OLS IV 
(1)
Coeff. 
(2) 
Robust std. err. 
(3)
Coeff. 
(4)
Robust std. err. 
TTD -0.041** 0.0013 -0.067** 0.0017 
Age -0.010** 0.0036 0.002 0.0036 
Age2/1000 0.223** 0.0291 0.107** 0.0298 
Sexm -0.660** 0.1887 -0.644* 0.1921 
Sexm*Age 0.025** 0.0064 0.025** 0.0065 
Sexm*Age2/1000 -0.231** 0.0525 -0.236** 0.0540 
Zurich -0.413** 0.0143 -0.418** 0.0144 
Accident insurance 0.213** 0.0144 0.219** 0.0144 
Higher deductible -0.181** 0.0118 -0.172** 0.0118 
Suppl. hospital cov. 0.034** 0.0119 0.039** 0.0120 
Other supplements -0.087** 0.0255 -0.070** 0.0258 
Constant 9.374** 0.1091 10.021** 0.1146 
Number of obs.  35,593 Number of obs. 35,593 
F (13, 35579)  650 F (13, 35579) 639 
Prob > F  0 Prob > F 0 
R-squared  0.1716 Centered squared 0.167 
Root MSE  1.0621 Root MSE 1.06 
 0.129 Hausman test of exogeneity
χ2 (1) = 28.45 (p = 0.00)  
The non-IV estimation results regarding the age effects confirm previous findings (see Zweifel
et al., 2004): although the coefficients pertaining to age are significant, the total marginal 
effect of age is small. Male have significantly lower HCE but the difference decreases with 
increasing age. In the IV estimation, the marginal effect of age becomes even smaller. The 
significant impact of TTD on HCE is reinforced, vindicating the findings of the ‘red herring’ 
literature.  
4. Explaining health care expenditure with expected time to death 
Past HCE, sex, age and characteristic of the insurance contract can explain as much as 35 
percent of an individual’s TTD (see col. 3 in Table 3). Therefore, TTD may have little 
explanatory power over and above past HCE. This issue is explored using model 2 (see 
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Figure 1 again), which relates HCE of 2003 to estimated TTD. The TTD  values come from 
eq. (1), with the period of observation moved forward from 2000 to 2002 and HCE  modified 
accordingly to be defined over the preceding 36 months. Table 6 contains the estimates for the 
Probit part. Comparing col. 1 with col. 1 of Table 4 shows coefficients to be robust despite the 
fact that ln HCE  and its square enter as regressors there. Remarkably, the explanatory power 
increases from 12.9 percent in Table 4 to 36.8 percent when observed TTD is replaced by 
TTD , derived from the variant of model 1 that includes past monthly HCE but excludes the 
individual’s survivor status. Most importantly however, TTD  continues to be highly 
significant.  
Table 6: Two-part model with TTD  (2003) 
 Probit (HCE > 230) OLS ln(HCE) | HCE > 230
(1)
Coeff. 
(2) 
SE 
(3)
Coeff. 
(4)
SE 
TTD 0.040** 0.011 -0.085** 0.004 
Age -0.008 0.006 0.037** 0.013 
Age2 0.216** 0.059 -0.483** 0.212 
Age3/1000   0.001** 0.001 
Sexm -0.232** 0.073 -0.129** 0.043 
Sexm*Age 0.003* 0.001 0.000** 0.001 
Zurich -0.037 0.027 -0.214** 0.012 
Accident insurance -0.007 0.019 0.001** 0.012 
Higher deductibles -0.313** 0.018 0.008** 0.010 
Suppl. hosp. cover. 0.043* 0.018 0.047** 0.010 
Other supplements 0.142** 0.036 0.064** 0.021 
ln HCE 0.071** 0.021 -0.311** 0.018 
( ln HCE )2 0.065** 0.004 0.074** 0.002 
Constant 0.065** 0.340 9.427** 0.270 
No. of obs. 46,299  No. of obs. 35,593 
Wald chi2 (13) 11,446  Wald chi2 (13) 2,936 
Pseudo R^2 0.368  Pseudo R^2 0.472 
   Root MSE 0.850 
As to the conditional HCE part, a comparison of cols. 3 of Table 4 and Table 6 again suggests 
a great deal of robustness. Also note that the explanatory power of the two estimations 
markedly increases once more when observed TTD is replaced by TTD . When average 
monthly HCE between 2000 and 2002 is included as explanatory variable for HCE in 2003, 
TTD keeps its high statistical significance while the model now explains almost 50 percent of 
the variance of annual HCE. This is substantially higher than what the pertinent literature 
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reports; Newhouse et al. (1989) found that due to the immanent randomness of demand, the 
maximum 2R  for explaining HCE is 5% for inpatient and 25% for outpatient care.  
Having established the explanatory power of TTD  over and above past HCE, one still needs 
to check the robustness of core ‘red herring’ findings with regard to the irrelevance of age as a 
predictor of HCE. In Figure 2, the age profile of men’s conditional positive HCE is illustrated 
for different values of TTD . For TTD  = 30, the profile is almost horizontal up to the age of 
60 years. Beyond that age, HCE slowly decreases. For TTD = 20, the age profile is falling 
beyond the age of 50, and for TTD  =10, the negative age gradient sets in at age 45. This 
pattern may be interpreted in the following way. Assume that treating physicians and/or their 
patients can predict time to death to the extent that they are able to distinguish between 10, 20, 
and 30 months remaining. Then, TTD  = 10 clearly indicates that chances of survival are 
relatively low, causing patients to give up pretty much regardless of age, i.e. at an early age 
such as 45. This causes HCE to stabilize at that age. By way of contrast, TTD  = 30 is a much 
less informative signal because ex ante there are still many chances of recovery. This means 
that it pays to fight up to a higher age such as 60, after which these efforts (and with them, 
HCE) taper off. 
Figure 2: Age profile of conditional positive HCE for different expected TTD 
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Compared to these small, second-order age effects in Figure 2, estimated proximity to death 
is far more important. HCE at TTD  = 10 is almost double the peak value of HCE at  
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TTD  = 20, which in turn almost doubles the peak value at TTD  = 30. Therefore, Figure 2
replicates two well-known properties of the cost of dying. First, they are large compared to 
any age effects, and second, they are decreasing beyond the age of 60 at the latest (Lubitz and 
Riley, 1993, Felder et al., 2000, Schellhorn et al., 2000, Chernichowski and Markowitz, 2004). 
This may be contrasted with the “naïve” approach that fails to control for time to death, 
represented by the curve that shows the lowest HCE up to age 65 but then crosses the other 
curves, steadily increasing throughout the life cycle. 
5. Conclusion 
This paper is devoted to an issue that has been undermining the credibility of the ‘red herring’ 
hypothesis, viz. that time-to-death (TTD) rather than age is a crucial determinant of individual 
health care expenditure (HCE). If HCE is effective, it should push the time of death away, 
thus increasing TTD. This would likely result in an overestimate of the effect of TTD on 
HCE. In model 1, monthly observations on HCE from 1997 to 1999 and individual and 
insurance contract characteristics are used to explain TTD measured from 2000 to the end of 
2002, with its maximum set at 36 months. Past HCE is found to have a positive effect on TTD 
except for the last month prior to death. Next, values of TTD estimated from model 1 might 
serve to replace observed values when it comes to explaining HCE of the year 2003. 
However, they fail a Hausman exogeneity test. Therefore, an Instrumental Variable estimation 
of model 2 which relates HCE of 2003 to the same variables shifted forward by three years 
must be imperfect. Still, estimated TTD retains its explanatory power in both components of a 
two-part model even when past HCE and its square enter as explanatory variables. Moreover, 
model 2 explains almost 50 percent of the variance in individual HCE, far more than reported 
in previous studies. Finally, the implied age gradient of HCE is flat, as predicted by the ‘red 
herring’ hypothesis.  
On the whole, while it proved impossible to fully purge TTD of its endogeneity, the empirical 
evidence supports the core claim of the ‘red herring’ hypothesis. Therefore, upward shifts in 
HCE over time are much more likely caused by advances in medical technology rather than 
ageing of the population. These advances, if applied to the aged or even the deathbound, 
could also be responsible for the so-called steepening of the age profile of HCE over time. 
Unfortunately, the data do not permit to investigate this intriguing conjecture. 
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